Xenon Pharmaceuticals's top three insider shareholders as of April 17, 2026 are Mohammad Azab (Director, 74.22K shares), Dawn Svoronos (Director, 25.00K shares), Gary Patou (Director, 23.57K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Mohammad Azab | - | 74,225 | 0 | 20 Dec, 2023 |
| Dawn Svoronos | - | 25,000 | 0 | 24 Aug, 2023 |
| Gary Patou | - | 23,573 | 0 | 22 Nov, 2024 |
| Ian Mortimer | President Ceo | 19,923 | 0 | 13 Mar, 2026 |
| James R. Empfield | Evp, Drug Discovery | 10,000 | 0 | 16 Aug, 2022 |
| Sherrington Robin | Evp, Strategy Innovation | 8,398 | 0 | 08 Mar, 2024 |
| Andrea Difabio | Chief Legal Officer | 7,301 | 0 | 13 Mar, 2026 |
| Steven Gannon | - | 7,141 | 0 | 06 Jun, 2025 |
| Christopher John Kenney | Chief Medical Officer | 7,069 | 0 | 13 Mar, 2026 |
| Simon N. Pimstone | Ceo | 6,000 | 0 | 01 Jun, 2023 |
| Gary Patou | - | 0 | 4,902 | 15 Dec, 2023 |
| Seggern Christopher Von | Chief Commercial Officer | 4,000 | 0 | 07 Dec, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 12 Mar, 2026 | Andrea Difabio | Common Shares | A | 3,750 | - | 8,643 | D | M |
| 12 Mar, 2026 | Ian Mortimer | Common Shares | A | 12,500 | - | 27,231 | D | M |
| 12 Mar, 2026 | Christopher John Kenney | Common Shares | A | 3,750 | - | 8,479 | D | M |
| 13 Mar, 2026 | Andrea Difabio | Common Shares | D | 1,342 | $55.23 | 7,301 | D | S |
| 13 Mar, 2026 | Ian Mortimer | Common Shares | D | 7,308 | $55.23 | 19,923 | D | S |
| 13 Mar, 2026 | Christopher John Kenney | Common Shares | D | 1,410 | $55.23 | 7,069 | D | S |
| 12 Mar, 2026 | Christopher John Kenney | Restricted Share Units | D | 3,750 | $0.00 | 11,250 | D | M |
| 12 Mar, 2026 | Andrea Difabio | Restricted Share Units | D | 3,750 | $0.00 | 11,250 | D | M |
| 12 Mar, 2026 | Ian Mortimer | Restricted Share Units | D | 12,500 | $0.00 | 37,500 | D | M |
| 09 Mar, 2026 | Andrea Difabio | Common Shares | A | 7,500 | - | 7,500 | D | M |
| 09 Mar, 2026 | Ian Mortimer | Common Shares | A | 75,000 | $8.40 | 81,000 | D | M |
| 09 Mar, 2026 | Christopher John Kenney | Common Shares | A | 7,500 | - | 7,500 | D | M |
| 10 Mar, 2026 | Christopher John Kenney | Common Shares | D | 2,771 | $60.11 | 4,729 | D | S |
| 10 Mar, 2026 | Andrea Difabio | Common Shares | D | 2,607 | $60.11 | 4,893 | D | S |
| 09 Mar, 2026 | Ian Mortimer | Common Shares | D | 21,791 | $58.81 | 59,209 | D | S |
| 09 Mar, 2026 | Christopher John Kenney | Performance Share Units | A | 7,500 | $0.00 | 7,500 | D | A |
| 09 Mar, 2026 | Ian Mortimer | Common Shares | D | 31,694 | $59.88 | 27,515 | D | S |
| 09 Mar, 2026 | Andrea Difabio | Performance Share Units | A | 7,500 | $0.00 | 7,500 | D | A |
| 09 Mar, 2026 | Ian Mortimer | Common Shares | D | 21,515 | $60.49 | 6,000 | D | S |
| 09 Mar, 2026 | Christopher John Kenney | Performance Share Units | D | 7,500 | $0.00 | 0 | D | M |